Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.
about
The Philadelphia chromosome in leukemogenesisInhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemiaJAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models.Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
P2860
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.
@en
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.
@nl
type
label
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.
@en
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.
@nl
prefLabel
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.
@en
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.
@nl
P2093
P2860
P50
P356
P1433
P1476
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.
@en
P2093
E Eckelhart
E Grundschober
K Kollmann
R L Levine
R Scheicher
P2860
P2888
P304
P356
10.1038/LEU.2014.152
P577
2014-05-05T00:00:00Z
P5875
P6179
1031453849